Results 201 to 210 of about 2,992,178 (408)
Cardiac resting and action potentials recorded with an intracellular electrode
, 1951 M. H. Draper, Silvio Weidmann
openalex +2 more sources
ON EXTRACELLULAR AND INTRACELLULAR VENOM ACTIVATORS OF THE BLOOD, WITH ESPECIAL REFERENCE TO LECITHIN AND FATTY ACIDS AND THEIR COMPOUNDS [PDF]
, 1907 Hideyo Noguchi
openalex +1 more source
MIF as an oncogenic driver of low‐heterogeneity melanomas
Molecular Oncology, EarlyView.Shvefel and colleagues identified tumor‐secreted macrophage migration inhibitory factor (MIF) as an upregulated cytokine that mediates immune resistance in melanomas with low‐intratumoral heterogeneity. MIF and its functional paralogue D‐dopachrome tautomerase (D‐DT or MIF‐2) have overlapping but nonidentical signaling functions and are hypothesized to
Thuy T. Tran +4 more
wiley +1 more source
THE INTRACELLULAR LOCALIZATION OF POLIOMYELITIS VIRUS [PDF]
, 1953 Albert S. Kaplan, Joseph L. Melnick
openalex +1 more source
Molecular Oncology, EarlyView.B‐cell chronic lymphocytic leukemia (B‐CLL) and monoclonal B‐cell lymphocytosis (MBL) show altered proteomes and phosphoproteomes, analyzed using mass spectrometry, protein microarrays, and western blotting. Identifying 2970 proteins and 316 phosphoproteins, including 55 novel phosphopeptides, we reveal BCR and NF‐kβ/STAT3 signaling in disease ...
Paula Díez +17 more
wiley +1 more source
The Intracellular Enzymes of Lower Fungi, Especially those of Penicillium Camemberti
, 1909 Arthur W. Dox
openalex +1 more source
IV. Tonsillar Tubercles Containing Intracellular Concretions Simulating Foreign Body Pseudotubercles [PDF]
, 1922 Carl Vernon Weller
openalex +1 more source
Targeted protein degradation in oncology: novel therapeutic opportunity for solid tumours?
Molecular Oncology, EarlyView.Current anticancer therapies are limited by the occurrence of resistance and undruggability of most proteins. Targeted protein degraders are novel, promising agents that trigger the selective degradation of previously undruggable proteins through the recruitment of the ubiquitin–proteasome machinery. Their mechanism of action raises exciting challenges,
Noé Herbel, Sophie Postel‐Vinay
wiley +1 more source
Molecular Oncology, EarlyView.Nuclear prothymosin α inhibits epithelial‐mesenchymal transition (EMT) in lung cancer by increasing Smad7 acetylation and competing with Smad2 for binding to SNAI1, TWIST1, and ZEB1 promoters. In early‐stage cancer, ProT suppresses TGF‐β‐induced EMT, while its loss in the nucleus in late‐stage cancer leads to enhanced EMT and poor prognosis.
Liyun Chen +12 more
wiley +1 more source
Studies of Extracellular and Intracellular Bacterial Deoxyribonucleic Acids
, 1958 B. Wesley Catlin, Lew Cunningham
openalex +1 more source